10039696Characterisation of BiologIC’s 3D printed biocomputer platform for advanced therapies, cellular agriculture and diagnosticsClosedCollaborative R&DInnovate UKBiologIC Technologies is developing the first world's biocomputer leveraging foundational IP and the latest additive manufacturing (3D printing) technologies. The first generation of the biocomputer is being developed to advance applications in diagnostics, advanced therapies, new vaccines and cultured meat and is designed to power the next generation of synthetic biology at scale. We use 3D printing as the fabrication process of the biocomputer platform. Multi-material 3D printing enables digital blending of materials (polymers and elastomers) that lets us produce a single system that integrates fluidics, electronics, optics and pneumatics into a single system. One of the challenges in bringing these systems to regulated markets such as manufacturing of advanced therapies is controlling the materials. BiologIC has developed proprietary knowhow regarding biocompatibility of the 3D printed system across each layer of its technology. Previous work has shown that BiologIC's post-processing methodologies can efficiently increase the biocompatibility of the 3D printed systems enabling molecular and cellular biology applications although further optimisation is desirable. By collaborating with external expertise through this project BiologIC will characterise the 3D printed components necessary for the further development of the biocomputer platform that will enable a paradigm shift in the production of synthetic biology, advanced therapies and diagnostics.